Navy Bean and Rice Bran Intake Alters the Plasma Metabolome of Children at Risk for Cardiovascular Disease

Katherine J Li, Erica C Borresen, NaNet Jenkins-Puccetti, Gary Luckasen, Elizabeth P Ryan, Katherine J Li, Erica C Borresen, NaNet Jenkins-Puccetti, Gary Luckasen, Elizabeth P Ryan

Abstract

Abnormal cholesterol in childhood predicts cardiovascular disease (CVD) risk in adulthood. Navy beans and rice bran have demonstrated efficacy in regulating blood lipids in adults and children; however, their effects on modulating the child plasma metabolome has not been investigated and warrants investigation. A pilot, randomized-controlled, clinical trial was conducted in 38 children (10 ± 0.8 years old) with abnormal cholesterol. Participants consumed a snack for 4 weeks containing either: no navy bean or rice bran (control); 17.5 g/day cooked navy bean powder; 15 g/day heat-stabilized rice bran; or 9 g/day navy beans and 8 g/day rice bran. Plasma metabolites were extracted using 80% methanol for global, non-targeted metabolic profiling via ultra-high performance liquid-chromatography tandem mass spectrometry. Differences in plasma metabolite levels after 4 weeks of dietary intervention compared to control and baseline were analyzed using analysis of variance and Welch's t-tests (p ≤ 0.05). Navy bean and/or rice bran consumption influenced 71 plasma compounds compared to control (p ≤ 0.05), with lipids representing 46% of the total plasma metabolome. Significant changes were determined for 18 plasma lipids in the navy bean group and 10 plasma lipids for the rice bran group compared to control, and 48 lipids in the navy bean group and 40 in the rice bran group compared to baseline. These results support the hypothesis that consumption of these foods impact blood lipid metabolism with implications for reducing CVD risk in children. Complementary and distinct lipid pathways were affected by the diet groups, including acylcarnitines and lysolipids (navy bean), sphingolipids (rice bran), and phospholipids (navy bean + rice bran). Navy bean consumption decreased free fatty acids associated with metabolic diseases (palmitate and arachidonate) and increased the relative abundance of endogenous anti-inflammatory lipids (endocannabinoids, N-linoleoylglycine, 12,13-diHOME). Several diet-derived amino acids, phytochemicals, and cofactors/vitamins with cardioprotective properties were increased compared to control and/or baseline, including 6-oxopiperidine-2-carboxylate (1.87-fold), N-methylpipecolate (1.89-fold), trigonelline (4.44- to 7.75-fold), S-methylcysteine (2.12-fold) (navy bean), salicylate (2.74-fold), and pyridoxal (3.35- to 3.96-fold) (rice bran). Findings from this pilot study support the need for investigating the effects of these foods for longer durations to reduce CVD risk.

Trial registration: clinicaltrials.gov (identifier NCT01911390).

Keywords: cardiovascular disease; children; cholesterol; metabolomics; navy bean; rice bran.

Figures

Figure 1
Figure 1
Participants in each dietary intervention group and the plasma samples used for metabolome analysis. CONSORT diagram shown in Borresen et al. (27). Reasons for withdrawal included: noncompliance to the study protocol (n = 5), declined to participate (n = 6), and gastrointestinal issues (n = 1).
Figure 2
Figure 2
Nutritional metabolome of children modulated by navy bean and/or rice bran consumption. (A) Total metabolite profile identified from plasma of children across all dietary groups. Total numbers of significantly modulated metabolites (increased and decreased, p ≤ 0.05) across eight metabolite classes after 4 weeks of navy bean, rice bran, or navy bean + rice bran consumption (B) compared to control group at 4 weeks or (C) compared to respective baseline.
Figure 3
Figure 3
Cytoscape pathway visualizations of lipid metabolites modulated by navy bean, rice bran, or navy bean + rice bran consumption. Lipid metabolites modulated by navy bean, rice bran, or navy bean + rice bran consumption for 4 weeks compared to control is shown in panels A,C,E respectively. Lipid metabolites modulated by navy bean, rice bran, or navy bean + rice bran consumption for 4 weeks compared to respective baseline is shown in panels B,D,F respectively. Nodes in red and blue represent significantly increased and decreased metabolites, respectively, compared to control or baseline (p ≤ 0.05). For each metabolite, the node diameter is proportional to the magnitude of the fold difference/change. Numerical values within nodes indicate the calculated pathway enrichment score. Pathways with enrichment scores greater than 1 were defined as being important contributors to overall dietary group differences (visualized in red/yellow).

References

    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation (2016) 133(4):e38–360.10.1161/CIR.0000000000000350
    1. Gooding HC, de Ferranti SD. Cardiovascular risk assessment and cholesterol management in adolescents: getting to the heart of the matter. Curr Opin Pediatr (2010) 22(4):398–404.10.1097/MOP.0b013e32833a6e22
    1. Berenson GS, Srinivasan SR, Bao W, Newman WPR, Tracy RE, Wattigney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med (1998) 338(23):1650–6.10.1056/NEJM199806043382302
    1. McGill HCJ, McMahan CA, Malcom GT, Oalmann MC, Strong JP. Effects of serum lipoproteins and smoking on atherosclerosis in young men and women. The PDAY Research Group. Pathobiological Determinants of Atherosclerosis in Youth. Arterioscler Thromb Vasc Biol (1997) 17(1):95–106.10.1161/01.ATV.17.1.95
    1. McGill HCJ, McMahan CA, Zieske AW, Malcom GT, Tracy RE, Strong JP. Effects of nonlipid risk factors on atherosclerosis in youth with a favorable lipoprotein profile. Circulation (2001) 103(11):1546–50.10.1161/01.CIR.103.11.1546
    1. Lauer RM, Lee J, Clarke WR. Predicting adult cholesterol levels from measurements in childhood and adolescence: the Muscatine Study. Bull N Y Acad Med (1989) 65(10):1127–42.
    1. Frontini MG, Srinivasan SR, Xu J, Tang R, Bond MG, Berenson GS. Usefulness of childhood non-high density lipoprotein cholesterol levels versus other lipoprotein measures in predicting adult subclinical atherosclerosis: the Bogalusa Heart Study. Pediatrics (2008) 121(5):924–9.10.1542/peds.2007-1472
    1. Nguyen D, Kit B, Carroll M. Abnormal cholesterol among children and adolescents in the United States, 2011–2014. NCHS Data Brief (2015) 228:1–8.
    1. U.S. Preventive Services Task Force. Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, Jr, et al. Screening for lipid disorders in children and adolescents: US preventive services task force recommendation statement. JAMA (2016) 316(6):625–33.10.1001/jama.2016.9852
    1. McGill HC, Jr, McMahan CA, Herderick EE, Malcom GT, Tracy RE, Strong JP. Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr (2000) 72(5 Suppl):1307S–15S.
    1. National Cholesterol Education Program. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on: Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). National Heart, Lung, and Blood Institute, National Institutes of Health; (2001). NIH Publication No.: 01-3670.
    1. Astarita G, Langridge J. An emerging role for metabolomics in nutrition science. J Nutrigenet Nutrigenomics (2013) 6(4–5):181–200.10.1159/000354403
    1. Ryan EP, Heuberger AL, Broeckling CD, Borresen EC, Tillotson C, Prenni JE. Advances in nutritional metabolomics. Curr Metabolomics (2013) 1(2):12.10.2174/2213235X11301020001
    1. Guertin KA, Moore SC, Sampson JN, Huang WY, Xiao Q, Stolzenberg-Solomon RZ, et al. Metabolomics in nutritional epidemiology: identifying metabolites associated with diet and quantifying their potential to uncover diet-disease relations in populations. Am J Clin Nutr (2014) 100(1):208–17.10.3945/ajcn.113.078758
    1. Chen H, Miao H, Feng YL, Zhao YY, Lin RC. Metabolomics in dyslipidemia. Adv Clin Chem (2014) 66:101–19.10.1016/B978-0-12-801401-1.00004-9
    1. Moco S, Collino S, Rezzi S, Martin FP. Metabolomics perspectives in pediatric research. Pediatr Res (2013) 73(4 Pt 2):570–6.10.1038/pr.2013.1
    1. Bartel J, Krumsiek J, Theis FJ. Statistical methods for the analysis of high-throughput metabolomics data. Comput Struct Biotechnol J (2013) 4:e201301009.10.5936/csbj.201301009
    1. Goffman FD, Pinson S, Bergman C. Genetic diversity for lipid content and fatty acid profile in rice bran. J Am Oil Chem Soc (2003) 80(5):6.10.1007/s11746-003-0725-x
    1. Messina V. Nutritional and health benefits of dried beans. Am J Clin Nutr (2014) 100(Suppl 1):437S–42S.10.3945/ajcn.113.071472
    1. Gul K, Yousul B, Singh AK, Singh P, Abas Wani A. Rice bran: nutritional values and its emerging potential for development of functional food – a review. Bioact Carbohydr Diet Fibre (2015) 6:7.10.1016/j.bcdf.2015.06.002
    1. Kris-Etherton PM, Hecker KD, Bonanome A, Coval SM, Binkoski AE, Hilpert KF, et al. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am J Med (2002) 113(Suppl 9B):71S–88S.10.1016/S0002-9343(01)00995-0
    1. Forster GM, Raina K, Kumar A, Kumar S, Agarwal R, Chen MH, et al. Rice varietal differences in bioactive bran components for inhibition of colorectal cancer cell growth. Food Chem (2013) 141(2):1545–52.10.1016/j.foodchem.2013.04.020
    1. Kahlon TS, Chow FI, Sayre RN, Betschart AA. Cholesterol-lowering in hamsters fed rice bran at various levels, defatted rice bran and rice bran oil. J Nutr (1992) 122(3):513–9.
    1. Chavez-Santoscoy RA, Gutierrez-Uribe JA, Granados O, Torre-Villalvazo I, Serna-Saldivar SO, Torres N, et al. Flavonoids and saponins extracted from black bean (Phaseolus vulgaris L.) seed coats modulate lipid metabolism and biliary cholesterol secretion in C57BL/6 mice. Br J Nutr (2014) 112(6):886–99.10.1017/S0007114514001536
    1. Zhang Z, Lanza E, Kris-Etherton PM, Colburn NH, Bagshaw D, Rovine MJ, et al. A high legume low glycemic index diet improves serum lipid profiles in men. Lipids (2010) 45(9):765–75.10.1007/s11745-010-3463-7
    1. Sanders TA, Reddy S. The influence of rice bran on plasma lipids and lipoproteins in human volunteers. Eur J Clin Nutr (1992) 46(3):167–72.
    1. Borresen EC, Jenkins-Puccetti N, Schmitz K, Brown DG, Pollack A, Fairbanks A, et al. A pilot randomized controlled clinical trial to assess tolerance and efficacy of navy bean and rice bran supplementation for lowering cholesterol in children. Glob Pediatr Health (2017) 4:1–10.10.1177/2333794X17694231
    1. Nelson TL, Puccetti N, Luckasen GJ. Healthy hearts: a cross-sectional study of clinical cardiovascular disease risk factors in Northern Colorado school children (1992–2013). BMC Obes (2015) 2:48.10.1186/s40608-015-0078-9
    1. Brown DG, Borresen EC, Brown RJ, Ryan EP. Heat-stabilised rice bran consumption by colorectal cancer survivors modulates stool metabolite profiles and metabolic networks: a randomised controlled trial. Br J Nutr (2017) 117(9):1244–56.10.1017/S0007114517001106
    1. Sheflin AM, Borresen EC, Wdowik MJ, Rao S, Brown RJ, Heuberger AL, et al. Pilot dietary intervention with heat-stabilized rice bran modulates stool microbiota and metabolites in healthy adults. Nutrients (2015) 7(2):1282–300.10.3390/nu7021282
    1. Borresen EC, Ryan EP. Rice bran: a food ingredient with global public health opportunities. 1st ed In: Watson RR, Preedy VR, Zibadi S, editors. Wheat and Rice in Disease Prevention and Health: Benefits, Risks, and Mechanisms of Whole Grains in Health Promotion. Oxford, UK: Elsevier; (2014). p. 301–11.
    1. Bazzano LA, Thompson AM, Tees MT, Nguyen CH, Winham DM. Non-soy legume consumption lowers cholesterol levels: a meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis (2011) 21(2):94–103.10.1016/j.numecd.2009.08.012
    1. Rozema E, Binder M, Bulusu M, Bochkov V, Krupitza G, Kopp B. Effects on inflammatory responses by the sphingoid base 4,8-sphingadienine. Int J Mol Med (2012) 30(3):703–7.10.3892/ijmm.2012.1035
    1. Cohn JS, Wat E, Kamili A, Tandy S. Dietary phospholipids, hepatic lipid metabolism and cardiovascular disease. Curr Opin Lipidol (2008) 19(3):257–62.10.1097/MOL.0b013e3282ffaf96
    1. Cohn JS, Kamili A, Wat E, Chung RW, Tandy S. Dietary phospholipids and intestinal cholesterol absorption. Nutrients (2010) 2(2):116–27.10.3390/nu2020116
    1. Steiber A, Kerner J, Hoppel CL. Carnitine: a nutritional, biosynthetic, and functional perspective. Mol Aspects Med (2004) 25(5–6):455–73.10.1016/j.mam.2004.06.006
    1. Bikman BT, Summers SA. Ceramides as modulators of cellular and whole-body metabolism. J Clin Invest (2011) 121(11):4222–30.10.1172/JCI57144
    1. Schooneman MG, Vaz FM, Houten SM, Soeters MR. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes (2013) 62(1):1–8.10.2337/db12-0466
    1. Jenkins DJ, Mirrahimi A, Srichaikul K, Berryman CE, Wang L, Carleton A, et al. Soy protein reduces serum cholesterol by both intrinsic and food displacement mechanisms. J Nutr (2010) 140(12):2302S–11S.10.3945/jn.110.124958
    1. Ramirez M, Amate L, Gil A. Absorption and distribution of dietary fatty acids from different sources. Early Hum Dev (2001) 65(Suppl):S95–101.10.1016/S0378-3782(01)00211-0
    1. Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol (2009) 31(1):63–77.10.1007/s00281-009-0145-8
    1. Burstein S, McQuain C, Salmonsen R, Seicol B. N-amino acid linoleoyl conjugates: anti-inflammatory activities. Bioorg Med Chem Lett (2012) 22(2):872–5.10.1016/j.bmcl.2011.12.040
    1. Osiecki H. The role of chronic inflammation in cardiovascular disease and its regulation by nutrients. Altern Med Rev (2004) 9(1):32–53.
    1. Lynes MD, Leiria LO, Lundh M, Bartelt A, Shamsi F, Huang TL, et al. The cold-induced lipokine 12,13-diHOME promotes fatty acid transport into brown adipose tissue. Nat Med (2017) 23(5):631–7.10.1038/nm.4297
    1. Hofmann AF. Bile acids: the good, the bad, and the ugly. News Physiol Sci (1999) 14:24–9.
    1. Hoppel C. The role of carnitine in normal and altered fatty acid metabolism. Am J Kidney Dis (2003) 41(4 Suppl 4):S4–12.10.1016/S0272-6386(03)00112-4
    1. Srinivasan M, Sudheer AR, Menon VP. Ferulic acid: therapeutic potential through its antioxidant property. J Clin Biochem Nutr (2007) 40(2):92–100.10.3164/jcbn.40.92
    1. Kumari K, Augusti KT. Antidiabetic and antioxidant effects of S-methyl cysteine sulfoxide isolated from onions (Allium cepa Linn) as compared to standard drugs in alloxan diabetic rats. Indian J Exp Biol (2002) 40(9):1005–9.
    1. Thomas S, Senthilkumar GP, Sivaraman K, Bobby Z, Paneerselvam S, Harichandrakumar KT. Effect of s-methyl-L-cysteine on oxidative stress, inflammation and insulin resistance in male Wistar rats fed with high fructose diet. Iran J Med Sci (2015) 40(1):45–50.
    1. Zhou J, Chan L, Zhou S. Trigonelline: a plant alkaloid with therapeutic potential for diabetes and central nervous system disease. Curr Med Chem (2012) 19(21):3523–31.10.2174/092986712801323171
    1. Hamden K, Mnafgui K, Amri Z, Aloulou A, Elfeki A. Inhibition of key digestive enzymes related to diabetes and hyperlipidemia and protection of liver-kidney functions by trigonelline in diabetic rats. Sci Pharm (2013) 81(1):233–46.10.3797/scipharm.1211-14
    1. Miyazawa T, Nakagawa K, Shimasaki S, Nagai R. Lipid glycation and protein glycation in diabetes and atherosclerosis. Amino Acids (2012) 42(4):1163–70.10.1007/s00726-010-0772-3
    1. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 354(15):1567–77.10.1056/NEJMoa060900
    1. Borresen EC, Brown DG, Harbison G, Taylor L, Fairbanks A, O’Malia J, et al. A randomized controlled trial to increase navy bean or rice bran consumption in colorectal cancer survivors. Nutr Cancer (2016) 68(8):1269–80.10.1080/01635581.2016.1224370
    1. Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clin Med Res (2014) 12(3–4):147–54.10.3121/cmr.2013.1197
    1. Frediani JK, Jones DP, Tukvadze N, Uppal K, Sanikidze E, Kipiani M, et al. Plasma metabolomics in human pulmonary tuberculosis disease: a pilot study. PLoS One (2014) 9(10):e108854.10.1371/journal.pone.0108854
    1. Armstrong AW, Wu J, Johnson MA, Grapov D, Azizi B, Dhillon J, et al. Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. F1000Res (2014) 3:248.10.12688/f1000research.4709.1
    1. Gahleitner F, Guallar-Hoyas C, Beardsmore CS, Pandya HC, Thomas CP. Metabolomics pilot study to identify volatile organic compound markers of childhood asthma in exhaled breath. Bioanalysis (2013) 5(18):2239–47.10.4155/bio.13.184
    1. Blaise BJ. Data-driven sample size determination for metabolic phenotyping studies. Anal Chem (2013) 85(19):8943–50.10.1021/ac4022314

Source: PubMed

3
구독하다